Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2025
Reporting Period: Second Quarter ended June 30, 2025
Context: The filing serves to announce the issuance of a press release containing financial results and a business update for the second quarter of 2025. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms that a press release containing these results was issued on August 12, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a business update and scheduled a conference call to discuss the second-quarter results. Specific commentary is contained within the referenced press release (Exhibit 99.1), not the 8-K body text.
Legal Disclaimer: The information furnished in this Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The Company explicitly states that furnishing this information does not constitute an admission that the information is material or complete.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for actual financial figures, as the 8-K text contains no numerical data.
- Verify the details of the conference call mentioned in the press release to hear management's direct commentary.
- Confirm the liquidity position and cash runway, as these are critical for a biotechnology firm but are not detailed in this summary filing.
- Check subsequent filings (e.g., 10-Q) for the audited or reviewed financial statements corresponding to the period ended June 30, 2025.